Day: February 23, 2021

– Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 –– Rilonacept in recurrent pericarditis granted priority review, with PDUFA goal date of March 21, 2021 –– Clinical data expected in 1H 2021 from KPL-404 (anti-CD40) Phase 1 clinical trial and mavrilimumab Phase 2 clinical trial in severe COVID-19 –– Year-end 2020 cash reserves of approximately $323 million –HAMILTON, Bermuda, Feb. 23, 2021 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today reported fourth quarter and full-year 2020 financial results and corporate and pipeline activity.“Kiniksa delivered outstanding...

OREM, Utah, Feb. 23, 2021 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for biotechnology, pharmaceutical, and transportation industries, announces a 23.7% year over year fourth quarter increase in sales.The 2020 fourth quarter sales of $695,823 showed an increase of 23.7% over the fourth quarter sales of $562,314 in 2019. These figures represent total fourth quarter sales for the company, although the largest contributor to this increase was the Cryometrix ULT freezer product line. Mr. Kim Boyce, CEO of Reflect Scientific Inc, commented, “We ended the year on a high note. Overall we were delighted with the sales for the fourth quarter of 2020.”About Reflect Scientific, Inc.Reflect Scientific, Inc., based in Orem, Utah, develops and markets innovative, proprietary technologies...

Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021Escalated the Dose in RTX-240 Phase 1 Clinical Trial in Relapsed/Refractory Acute Myeloid LeukemiaScreening Patients in RTX-321 Phase 1 Clinical Trial in Advanced Human Papillomavirus 16-Positive CancersCAMBRIDGE Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reported fourth quarter and full year 2020 financial results and provided a business update.“Last year was one of strong execution for Rubius Therapeutics as we advanced our clinical trials in oncology and...

MADRID, Spain and CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fourth quarter of 2020 and provided an update on recent developments.Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon made strong progress in 2020, achieving a number of important clinical milestones that further our pioneering work in personalized medicine in epigenetics. New clinical data in acute myeloid leukemia corroborate the strong clinical activity of iadademstat and signals a clear path ahead for the development of the molecule in oncology. In CNS, the regulatory green light to start our first Phase IIb study in borderline...